MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by STERN, P. H.
Right arrow Articles by DELUCA, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by STERN, P. H.
Right arrow Articles by DELUCA, H. F.

Molecular Pharmacology, Vol 12, 879-886, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Bone-Resorbing Activity of Analogues of 25-Hydroxycholecalciferol and 1,25-Dihydroxycholecalciferol: Effects of Side Chain Modification and Stereoisomerization on Responses of Fetal Rat Bones in Vitro

PAULA H. STERN 1, THALIA MAVREAS 1, CLARENCE L. TRUMMEL 2, HEINRICH K. SCHNOES 3, and HECTOR F. DELUCA 1

1 Department of Pharmacology, Northwestern University Medical School, Chicago, Illinois 60611
2 Department of Pharmacology and Toxicology, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14620
3 Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53706

Organ cultures of fetal rat bone were used to test the effects of molecular modification on the bone-resorbing activity of the vitamin D3 metabolites 25-OH-D3 and 1,25-(OH)2D3. Addition of 26-hydroxyl group to the 25-OH-D3 side chain reduced the activity more than 10-fold. Shortening the 25-OH-D3 side chain by 1 carbon atom reduced the activity by at least two orders of magnitude. Removal of the 26- and 27-methyl groups diminished the bone-resorbing activity still further. 1,25-(OH)2D3 was likewise more active than the vitamin D3 derivatives with which it was compared. The 3agr-hydroxy epimer of 1,25-(OH)2D3 [1,25-(OH)2D3 (3agr)] was more than three orders of magnitude less active than 1,25-(OH)2D3. 1,24(R),25-(OH)3D3 was approximately 1/10 as active as 1,25-(OH)2D3. When the 24-hydroxyl was in the S configuration, the trihydroxy derivative was even less effective. 1,25-(OH)2D3 was approximately equiactive with 1,25-(OH)2D2. The results illustrate the importance of precise structural characteristics at a number of sites on the molecule for optimal bone-resorbing activity. The data also show that in terms of direct effects on bone, no known naturally occurring vitamin D3 metabolite or synthetic congener surpasses 1,25-(OH)2D3 in activity. A striking correlation exists between the structure-activity relationships shown here and published studies on the binding of vitamin D analogues to subcellular "receptors." Good correlations also can be demonstrated between effects of the 1-hydroxylated derivatives on bone resorption in vivo and in vitro. Greater inconsistencies between results in vitro and in vivo are found with compounds lacking a 1-hydroxyl group.

Submitted on April 1, 1976
Accepted on May 25, 1976




This article has been cited by other articles:


Home page
ScienceHome page
H. Gelbard, P. Stern, and D. U'Prichard
1 alpha, 25-Dihydroxyvitamin D3 nuclear receptors in pituitary
Science, September 12, 1980; 209(4462): 1247 - 1249.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics